Humana (NYSE:HUM) Trading Down 2.9% - Time to Sell?

Humana Inc. (NYSE:HUM - Get Free Report) shares traded down 2.9% on Monday . The company traded as low as $288.00 and last traded at $286.51. 153,686 shares traded hands during trading, a decline of 91% from the average session volume of 1,746,191 shares. The stock had previously closed at $295.04.

Wall Street Analyst Weigh In

• MarketBeat Week in Review – 02/17 - 02/21

HUM has been the subject of several research reports. Cantor Fitzgerald reissued a "neutral" rating and issued a $290.00 price objective on shares of Humana in a research report on Wednesday, February 12th. Truist Financial increased their price objective on Humana from $290.00 to $325.00 and gave the stock a "hold" rating in a research note on Friday. Royal Bank of Canada reaffirmed an "outperform" rating and set a $283.00 target price on shares of Humana in a research report on Wednesday, February 12th. StockNews.com raised Humana from a "hold" rating to a "buy" rating in a research report on Monday, April 7th. Finally, Morgan Stanley decreased their price objective on Humana from $301.00 to $285.00 and set an "equal weight" rating for the company in a report on Wednesday, February 12th. Seventeen analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $288.60.

Check Out Our Latest Research Report on Humana

Humana Price Performance

• Humana Gains Despite Medicare Advantage Losses—What’s the Catch?

The company has a market cap of $34.24 billion, a PE ratio of 28.52, a price-to-earnings-growth ratio of 2.05 and a beta of 0.62. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The stock has a 50 day moving average of $265.55 and a 200-day moving average of $270.35.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. Equities analysts predict that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

• Cigna Misses EPS: What It Means for the Health Insurance Industry

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.25%. The ex-dividend date of this dividend is Friday, March 28th. Humana's payout ratio is currently 35.58%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in HUM. Dodge & Cox lifted its holdings in Humana by 106.7% during the fourth quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider's stock valued at $2,587,345,000 after purchasing an additional 5,264,045 shares in the last quarter. Vanguard Group Inc. lifted its stake in Humana by 15.8% in the 4th quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider's stock valued at $3,254,899,000 after buying an additional 1,751,857 shares in the last quarter. Norges Bank acquired a new stake in Humana in the 4th quarter worth about $416,202,000. Pzena Investment Management LLC increased its stake in Humana by 44.0% during the 4th quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider's stock worth $915,736,000 after buying an additional 1,103,132 shares in the last quarter. Finally, Boston Partners raised its holdings in shares of Humana by 435.8% during the fourth quarter. Boston Partners now owns 1,098,702 shares of the insurance provider's stock valued at $279,236,000 after acquiring an additional 893,637 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company's stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Articles

• Five stocks we like better than Humana
• How to Choose Top Rated Stocks
• Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold
• Expert Stock Trading Psychology Tips
• 3 Hot New IPOs Defying the 2025 Market Slump
• How Can Investors Benefit From After-Hours Trading
• 3 High-Yield Dividend Stocks Trading at a Discount

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Humana Right Now?

Before you consider Humana, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.

While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here